Top news of the week: 14.10.2021.
Career And Jobs
CRISPR Therapeutics claims safety advantage in first big look at off-the-shelf CAR-T data, but durability in question
CRISPR Therapeutics CEO Samarth Kulkarni thinks his company might have built the safest CAR-T therapy yet. The gene editing biotech announced the first major batch of data from its ...
AI Tool Named Higashi Sweetens Analysis of Single-Cell Hi-C Data
A new algorithm, named Higashi, used in conjunction with single cell Hi-C, provides a high-definition analysis of genome organization in single cells.
Biotech Halftime Report: After a bumpy year, is biotech ready to rebound?
The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, ...
SOSV’s IndieBio — New York’s Latest Launch Pad for Early-Stage Biotech
The commercial life sciences sector is entering a golden age in New York City, marked by explosive growth in the industry. New York’s life…
Takeda Doubles Down on Biotech Partnerships with Immusoft and Poseida
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS ...
Boston biotech backers quit Dana-Farber board after U-turn on investment policy: report
Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a ...
Stakeholder Collaborations Essential to Making Things Happen in Rare Disease Space
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
Biden's fight with Moderna over providing vaccines for the poorest countries intensifies
With about $10 billion in taxpayer funds invested in Moderna so far, it would seem that the company would be more understanding of pleas from President Joe Biden and the federal government ...